Description

Ipamorelin is a pentapeptide and a potent, highly selective ghrelin receptor agonist. As a third-generation growth hormone secretagogue, Ipamorelin is distinct in its ability to stimulate the pituitary gland to release endogenous growth hormone (GH) without significantly impacting the secretion of cortisol, prolactin, or aldosterone.

Performance Peptides Canada provides 10mg Ipamorelin vials at 99%+ purity, verified by batch-specific HPLC and Mass Spectrometry. Our domestic fulfillment ensures that researchers receive laboratory-grade ligands with the chemical stability required for precise endocrine signaling studies.

Technical Specifications & Chemical Profile

Synthesized to meet the highest analytical benchmarks, our Ipamorelin 10mg vials follow these specifications:

• Molecular Formula: C₃₃H₄₇N₁₁O₉
• Molecular Weight: 711.85 Da
• Amino Acid Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2
• CAS Number: 170851-70-4
• Purity: ≥99.0% (Verified via HPLC/MS)
• Structure: Small molecule pentapeptide mimic.

Primary Research Mechanisms & Selectivity

Ipamorelin is a primary entity in somatotropic research due to its unique interaction with the Growth Hormone Secretagogue Receptor (GHSR-1a).

1. Selective GHSR-1a Agonism

Ipamorelin acts as a selective ligand for the ghrelin receptor in the pituitary and hypothalamus. Unlike earlier GHRPs (Growth Hormone Releasing Peptides), Ipamorelin does not trigger the “hunger response” associated with ghrelin to the same degree, nor does it stimulate the release of ACTH (Adrenocorticotropic hormone). This allows researchers to isolate the effects of pulsatile GH release without the confounding variables of elevated cortisol.

2. Somatotropic Signaling & Pulsatile Release

In laboratory models, Ipamorelin mimics the natural pulsatile release of growth hormone. It works synergistically with endogenous Growth Hormone-Releasing Hormone (GHRH) while simultaneously suppressing Somatostatin (the hormone responsible for inhibiting GH release). This makes it a vital tool for studying bone density, muscle mass preservation, and nitrogen retention.

3. Bone Mineral Density & Gastric Motility

Beyond its endocrine effects, Ipamorelin is studied for its impact on osteoblast activity. Research suggests it may influence bone mineral content and mineralization processes. Additionally, as a ghrelin mimetic, it is investigated for its potential to improve gastric motility in postoperative or metabolic dysfunction models.

Reconstitution & Laboratory Handling

To preserve the biological activity of the pentapeptide, follow these handling protocols:

• Reconstitution: Recommended diluent is Bacteriostatic Water or 0.9% Sterile Saline.
• Method: Gently introduce 2–3mL of diluent. Allow the liquid to flow down the side of the vial. Do not shake; a slow, circular motion is sufficient to dissolve the lyophilized cake.
• Avoid Degradation: Peptides are sensitive to high-frequency vibrations (ultrasonication) and extreme temperature changes.

Stability & Storage Benchmarks

Note: For optimal results, use reconstituted Ipamorelin within 14 days and store it in a light-protected environment to prevent photo-degradation.

Ipamorelin Research FAQ

Q: How does Ipamorelin differ from GHRP-6?

A: Ipamorelin is significantly more selective than GHRP-6. While GHRP-6 can cause a massive spike in hunger and elevate cortisol and prolactin levels, Ipamorelin is “cleaner,” stimulating GH release without these off-target effects, making it a superior choice for controlled research.

Q: Can Ipamorelin be studied alongside CJC-1295?

A: Yes. This is a common research “stack.” CJC-1295 (a GHRH analog) and Ipamorelin (a GHRP) work synergistically; one increases the total number of GH-secreting cells (GHRH), while the other triggers the actual pulse (GHRP).

Q: Is your Ipamorelin batch-tested?

A: Absolutely. Performance Peptides Canada provides a batch-specific COA for every 10mg vial. We use third-party HPLC and MS to guarantee that our Ipamorelin exceeds 99% purity.